FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W35642494> ?p ?o ?g. }

• W35642494 endingPage "3" @default.
• W35642494 startingPage "1391" @default.
• W35642494 abstract "Misoprostol is an effective agent for cervical ripening and induction of labor. The use of oxytocin was significantly decreased in patients treated with misoprostol versus dinoprostone. It has been used to induce over 1000 women in reported studies and has demonstrated a safety profile comparable with that of endocervical and vaginal dinoprostone. Uterine hyperstimulation was a concern in earlier trials, but at a reduced dose of 25 micrograms, the incidence has decreased to a level that is comparable with the values reported for dinoprostone. Misoprostol tablets are stable at room temperature and are considerably less expensive than the dinoprostone alternatives. Two additional factors pertaining to misoprostol administration must be taken into account before the drug is selected for vaginal use. First, Cytotec tablets are currently available in two strengths, 100 and 200 micrograms. This can lead to confusion or error if the clinician orders a quarter or half tablet. The order should always identify the strength in micrograms (25 or 50 micrograms). Second, the 100-microgram tablet is not scored; therefore, the proper dose should be carefully prepared by a pharmacist using a pill cutter. Key members of the hospital staff must be trained about the proper use of misoprostol for labor induction before initiating therapy. One alternative to directly inserting the tablet is to pulverize it and mix with a gel such as hydroxyethylcellulose gel. However, such compounding introduces the same problems with stability and uniformity of dose as experienced with dinoprostone gels. Despite the success of misoprostol in clinical trials, it is not approved for this indication, and the manufacturer of Cytotec does not plan to pursue approval. Therefore, independent, large-scale studies are warranted to more accurately assess the efficacy and overall safety of using intravaginal alprostadil for cervical ripening and labor induction. Additional clinical experience should also help to determine the best regimen and method of administration. From the data currently available, it appears that either a 25- or 50-microgram dose (one-fourth or one-half of a 100-microgram tablet) inserted into the posterior vaginal fornix and repeated at 4-5-hour intervals if needed, is a clinically effective regimen, and is associated with the least amount of adverse effects and complications. As with all labor inductions, uterine contractions and fetal heart rate should be monitored carefully throughout the procedure." @default.
• W35642494 created "2016-06-24" @default.
• W35642494 creator A5001775034 @default.
• W35642494 creator A5011047705 @default.
• W35642494 creator A5032511525 @default.
• W35642494 date "1997-11-01" @default.
• W35642494 modified "2023-09-23" @default.
• W35642494 title "Vaginal misoprostol for term labor induction." @default.
• W35642494 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9391696" @default.
• W35642494 hasPublicationYear "1997" @default.
• W35642494 type Work @default.
• W35642494 sameAs 35642494 @default.
• W35642494 citedByCount "7" @default.
• W35642494 crossrefType "journal-article" @default.
• W35642494 hasAuthorship W35642494A5001775034 @default.
• W35642494 hasAuthorship W35642494A5011047705 @default.
• W35642494 hasAuthorship W35642494A5032511525 @default.
• W35642494 hasConcept C126322002 @default.
• W35642494 hasConcept C131872663 @default.
• W35642494 hasConcept C2776176026 @default.
• W35642494 hasConcept C2777956040 @default.
• W35642494 hasConcept C2778642596 @default.
• W35642494 hasConcept C2779199973 @default.
• W35642494 hasConcept C2779234561 @default.
• W35642494 hasConcept C2910976051 @default.
• W35642494 hasConcept C54355233 @default.
• W35642494 hasConcept C71924100 @default.
• W35642494 hasConcept C86803240 @default.
• W35642494 hasConceptScore W35642494C126322002 @default.
• W35642494 hasConceptScore W35642494C131872663 @default.
• W35642494 hasConceptScore W35642494C2776176026 @default.
• W35642494 hasConceptScore W35642494C2777956040 @default.
• W35642494 hasConceptScore W35642494C2778642596 @default.
• W35642494 hasConceptScore W35642494C2779199973 @default.
• W35642494 hasConceptScore W35642494C2779234561 @default.
• W35642494 hasConceptScore W35642494C2910976051 @default.
• W35642494 hasConceptScore W35642494C54355233 @default.
• W35642494 hasConceptScore W35642494C71924100 @default.
• W35642494 hasConceptScore W35642494C86803240 @default.
• W35642494 hasIssue "11" @default.
• W35642494 hasLocation W356424941 @default.
• W35642494 hasOpenAccess W35642494 @default.
• W35642494 hasPrimaryLocation W356424941 @default.
• W35642494 hasRelatedWork W2014933149 @default.
• W35642494 hasRelatedWork W2073544748 @default.
• W35642494 hasRelatedWork W2257755953 @default.
• W35642494 hasRelatedWork W2357926096 @default.
• W35642494 hasRelatedWork W2414818233 @default.
• W35642494 hasRelatedWork W2998555809 @default.
• W35642494 hasRelatedWork W3193851700 @default.
• W35642494 hasRelatedWork W2050791503 @default.
• W35642494 hasRelatedWork W2186957778 @default.
• W35642494 hasRelatedWork W2591749785 @default.
• W35642494 hasVolume "31" @default.
• W35642494 isParatext "false" @default.
• W35642494 isRetracted "false" @default.
• W35642494 magId "35642494" @default.
• W35642494 workType "article" @default.